Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : GSK source : Www.globenewswire.com save search
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
Published: 2024-02-22 (Crawled : 18:00) - globenewswire.com
ALSMY | News | $1.59 -1.78% 490K
|
Manufacturing
|
| O: 0.0%
H: 0.56%
C: 0.0%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.45%
H: 0.24%
C: -0.31%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
Published: 2024-02-08 (Crawled : 12:00) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: -0.48%
H: 0.16%
C: 0.0%
ALEC | $5.18 1.77% 1.74% 350K
|
Health Technology
|
| O: 0.0%
H: 2.34%
C: -2.34%
al101 first disease alzheimer’s trial
23andMe Reports Third Quarter Fiscal 2024 Financial Results
Published: 2024-02-07 (Crawled : 21:00) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: -0.48%
H: 0.16%
C: 0.0%
financial results
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
Published: 2024-02-07 (Crawled : 12:00) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.43%
H: 0.67%
C: 0.21%
ALEC | $5.18 1.77% 1.74% 350K
|
Health Technology
|
| O: 2.15%
H: 5.51%
C: 3.73%
fda dementia designation grants therapy
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-13 (Crawled : 22:00) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.12%
H: 0.14%
C: -0.49%
SCYX | $1.47 2.08% 2.04% 73K
|
Health Technology
|
| O: 0.29%
H: 4.94%
C: -0.58%
update financial results
23andMe Reports Second Quarter Fiscal 2024 Financial Results
Published: 2023-11-08 (Crawled : 21:00) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.0%
H: 0.03%
C: -1.71%
financial results
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
Published: 2023-10-30 (Crawled : 12:00) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 2.29%
H: 0.44%
C: -0.23%
collaboration extension agreement
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
Published: 2023-10-27 (Crawled : 11:00) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: -2.46%
ALEC | $5.18 1.77% 1.74% 350K
|
Health Technology
|
| O: 0.76%
H: 0.38%
C: -3.57%
dementia trial
Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
Published: 2023-10-03 (Crawled : 12:00) - globenewswire.com
CNTA | News | $10.0 -5.39% -5.7% 210K
|
Manufacturing
|
| O: 1.25%
H: 1.93%
C: -2.99%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.25%
H: 0.08%
C: -0.8%
pharmaceuticals
Mersana Therapeutics Announces Changes in Leadership
Published: 2023-09-06 (Crawled : 11:00) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.12%
H: 0.06%
C: -0.55%
MRSN | $3.16 -2.77% -2.85% 1.8M
|
Health Technology
|
| O: 0.0%
H: 9.65%
C: 7.89%
therapeutics
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
Published: 2023-08-21 (Crawled : 11:00) - globenewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.0%
H: 0.68%
C: 0.68%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.26%
H: 0.23%
C: -0.03%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 2.54%
H: 0.0%
C: 0.0%
FOLD F | $10.83 2.07% 2.03% 3.7M
|
Health Technology
|
| O: 0.71%
H: 0.66%
C: -1.56%
therapeutics financial simon
Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer
Published: 2023-06-14 (Crawled : 12:00) - globenewswire.com
PFE | News A | $26.26 1.0% -0.08% 36M
|
Health Technology
|
| O: 0.1%
H: 0.05%
C: -2.38%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.29%
H: 0.09%
C: -0.78%
SPRO | $1.405 0.36% 0.36% 290K
|
Health Technology
|
| O: 0.0%
H: 0.58%
C: -5.81%
therapeutics
Erasca Further Strengthens Business Leadership with Two Key Promotions
Published: 2023-05-16 (Crawled : 12:00) - globenewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.7%
H: 3.06%
C: 3.06%
ERAS | $1.85 3.35% 3.24% 330K
|
|
| O: -0.68%
H: 0.68%
C: -3.4%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: -0.9%
H: 0.6%
C: 0.05%
business
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
Published: 2023-05-12 (Crawled : 12:00) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 1.6%
H: 0.69%
C: -0.9%
SCYX | $1.47 2.08% 2.04% 73K
|
Health Technology
|
| O: 1.45%
H: 1.08%
C: -0.36%
brexafemme license agreement
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
Published: 2023-05-11 (Crawled : 15:20) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: -0.88%
H: 0.25%
C: 0.19%
SWTX | $42.87 6.91% 6.46% 850K
|
Health Technology
|
| O: -0.92%
H: 8.12%
C: 7.7%
association therapeutics
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
Published: 2023-05-10 (Crawled : 11:00) - globenewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: -0.03%
H: 0.38%
C: 0.25%
ZNTL | $13.015 0.42% 0.42% 450K
|
Health Technology
|
| O: 2.59%
H: 4.49%
C: 4.23%
pharmaceuticals financial results
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting
Published: 2023-04-26 (Crawled : 14:20) - globenewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -4.57%
H: 0.22%
C: -1.98%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: -0.03%
H: 0.3%
C: -2.63%
ZNTL | $13.015 0.42% 0.42% 450K
|
Health Technology
|
| O: -0.23%
H: 0.18%
C: -1.43%
asco positive cancer meeting
Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones
Published: 2023-01-06 (Crawled : 12:20) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: -0.44%
H: 1.85%
C: 1.72%
MRSN | $3.16 -2.77% -2.85% 1.8M
|
Health Technology
|
| O: 1.33%
H: 5.9%
C: 3.93%
expected therapeutics update
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
Published: 2022-11-08 (Crawled : 13:20) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.53%
H: 1.2%
C: 0.34%
SPRO | $1.405 0.36% 0.36% 290K
|
Health Technology
|
| O: 6.19%
H: 4.13%
C: -5.34%
license therapeutics agreement
SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma
Published: 2022-09-07 (Crawled : 14:00) - globenewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: -0.83%
H: 1.22%
C: 0.9%
SWTX | $42.87 6.91% 6.46% 850K
|
Health Technology
|
| O: -0.38%
H: 15.79%
C: 7.56%
expansion collaboration
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.